Tesco Pension Investment Ltd Has $82.53 Million Stake in Johnson & Johnson (NYSE:JNJ)

Tesco Pension Investment Ltd lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 48.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 464,910 shares of the company’s stock after selling 444,199 shares during the period. Johnson & Johnson comprises about 4.8% of Tesco Pension Investment Ltd’s investment portfolio, making the stock its 4th largest position. Tesco Pension Investment Ltd’s holdings in Johnson & Johnson were worth $82,526,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. DORCHESTER WEALTH MANAGEMENT Co increased its stake in Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P increased its stake in Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares during the last quarter. IFM Investors Pty Ltd increased its stake in Johnson & Johnson by 20.1% during the first quarter. IFM Investors Pty Ltd now owns 418,999 shares of the company’s stock valued at $74,259,000 after purchasing an additional 70,221 shares during the last quarter. Essex LLC boosted its holdings in shares of Johnson & Johnson by 3.7% during the first quarter. Essex LLC now owns 32,274 shares of the company’s stock valued at $5,720,000 after acquiring an additional 1,146 shares during the period. Finally, Strategic Financial Services Inc boosted its holdings in shares of Johnson & Johnson by 3.5% during the first quarter. Strategic Financial Services Inc now owns 22,903 shares of the company’s stock valued at $4,059,000 after acquiring an additional 780 shares during the period. Institutional investors own 68.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JNJ. Raymond James reduced their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. SVB Leerink reduced their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Barclays began coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target for the company. Finally, Bank of America reduced their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $184.25.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. In the last quarter, insiders have sold 118,795 shares of company stock worth $20,230,174. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $169.25 on Monday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $442.50 billion, a P/E ratio of 23.57, a PEG ratio of 3.46 and a beta of 0.57. The company has a 50-day simple moving average of $166.88 and a 200 day simple moving average of $171.51.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. During the same period in the prior year, the company earned $2.60 EPS. Johnson & Johnson’s revenue was up 1.9% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a yield of 2.67%. Johnson & Johnson’s payout ratio is presently 62.95%.

Johnson & Johnson declared that its Board of Directors has authorized a share repurchase plan on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.